Vertex Shareholders Stay Vexed

New clinical data from Vertex Pharmaceuticals (VRTX Quote) regarding its hepatitis C drug telaprevir, expected at a medical meeting next month, seem to have investors on edge.

Shares of the Cambridge, Mass.-based biotech firm continue show weakness on worries that telaprevir won't live up to expectations when new phase II data are presented at the European Association for the Study of Liver Disease meeting on April 11-15.

I last wrote about telaprevir in early February with Vertex shares at $35, at the time down from a recent high of $44. On Tuesday, the stock closed up 20 cents at $27.85. ...